AXQ Capital LP Takes Position in Revvity Inc. $RVTY

AXQ Capital LP purchased a new stake in Revvity Inc. (NYSE:RVTY) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 5,492 shares of the company’s stock, valued at approximately $481,000.

A number of other hedge funds also recently bought and sold shares of RVTY. CYBER HORNET ETFs LLC purchased a new stake in shares of Revvity in the second quarter valued at approximately $32,000. MUFG Securities EMEA plc acquired a new stake in Revvity in the 2nd quarter valued at $34,000. Headlands Technologies LLC purchased a new stake in Revvity in the 2nd quarter worth $49,000. Smartleaf Asset Management LLC raised its position in Revvity by 56.8% during the third quarter. Smartleaf Asset Management LLC now owns 690 shares of the company’s stock worth $58,000 after acquiring an additional 250 shares during the period. Finally, Quent Capital LLC acquired a new position in Revvity during the third quarter worth $71,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Price Performance

NYSE:RVTY opened at $97.54 on Wednesday. Revvity Inc. has a one year low of $81.36 and a one year high of $120.39. The stock has a market cap of $11.06 billion, a PE ratio of 46.89, a P/E/G ratio of 2.06 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.40 and a current ratio of 1.68. The stock has a 50 day moving average price of $103.20 and a 200 day moving average price of $96.30.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Monday, February 2nd. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. Revvity had a return on equity of 7.92% and a net margin of 8.45%.The company had revenue of $772.06 million for the quarter, compared to analyst estimates of $759.81 million. During the same quarter in the previous year, the company posted $1.42 earnings per share. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. Equities research analysts expect that Revvity Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 8th. Investors of record on Friday, April 17th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date is Friday, April 17th. Revvity’s dividend payout ratio (DPR) is presently 13.46%.

Analysts Set New Price Targets

A number of research firms have recently commented on RVTY. JPMorgan Chase & Co. boosted their target price on shares of Revvity from $100.00 to $105.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 3rd. Bank of America lowered Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price objective for the company. in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d)” rating on shares of Revvity in a report on Monday, December 29th. Barclays lifted their price target on Revvity from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 3rd. Finally, The Goldman Sachs Group assumed coverage on Revvity in a research note on Tuesday, December 9th. They issued a “neutral” rating and a $105.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Revvity currently has a consensus rating of “Hold” and a consensus price target of $113.67.

Revvity Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.